Here are relevant reports on : prostate-cancer-diagnostics-market
-
Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030
Global respiratory diagnostics market valued at $5.84B in 2024, reached $6.17B in 2025, and is projected to grow at a robust 6.5% CAGR, hitting $9.02B by 2030. The major factors driving the growth of this market include the rising incidence of respiratory disorders, the expanding geriatric population and the rise in sedentary lifestyles, growing awareness about respiratory health, and advancements in diagnostic technologies.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
Immuno Oncology Assays Market Size, Share & Trends by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026
The size of global immuno oncology assays market in terms of revenue was estimated to be worth USD 4.4 billion in 2021 and is poised to reach USD 7.9 billion by 2026, growing at a CAGR of 12.5% from 2021 to 2026. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics)-Forecast to 2030
The predictive clinical biomarkers market, valued at US$7.84 billion in 2024, stood at US$8.49 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$14.69 billion by the end of the period. he market for predictive clinical biomarkers is growing rapidly as the healthcare industry shifts toward personalized and predictive medicine.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Immunohistochemistry Market by Product & Service (Antibodies (Type (Primary), Clonality (Monoclonal), Regulatory Class, Reagents, Kits, Instruments (Stainers), Software)), Application (Diagnostics (Cancer), Research, Forensics) - Global Forecast to 2030
The global immunohistochemistry market, valued at US$3.31 billion in 2024, stood at US$3.55 billion in 2025 and is projected to advance at a resilient CAGR of 7.6% from 2025 to 2030, culminating in a forecasted valuation of US$5.14 billion by the end of the period. The increasing number of cancer cases is one of the key factors driving the uptake of IHC products, which, in turn, leads to a greater need for accurate and efficient diagnostic tools such as IHC tests.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Womens Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care) & Region - Global Forecast to 2025
The global womens health diagnostics market growth is primed to transition from $25.0 billion in 2020 to $36.6 billion by 2025, showcasing a strong CAGR of 7.9%. The market growth is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe.
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
Urinary Catheters Market by Product (Indwelling, Intermittent, External), Type (Coated, Uncoated), Application (Urinary Incontinence, Benign Prostate Hyperplasia, General Surgery), Usage (Male, Female), End User (Hospitals) & Region - Global Forecast to 2025
The global urinary catheters market in terms of revenue was estimated to be worth $2.0 billion in 2020 and is poised to reach $2.6 billion by 2025, growing at a CAGR of 5.5% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
- Published: September 2020
- Price: $ 4950
- TOC Available:
-
Intensity Modulated Radiotherapy Market by Radiation Type (Photon, Electron Beam, Proton and Carbon-Ion Radiation) Application (Prostate, Lung, Breast), End Users ( Hospitals and Independent Radiotherapy centers), and Region - Global Forecast to 2028
The global intensity modulated radiotherapy market, valued at US$2.1B in 2022, is forecasted to grow at a 5.2% CAGR, reaching US$2.2B by 2023 and US$2.8B by 2028. Rising demand for intensity-modulated interventions and growth in non-invasive treatments of cancer management are a few drivers that collectively contribute to the growth of intensity-modulated radiotherapy, and as healthcare technologies continue to evolve, the demand for intensity-modulated radiotherapy is expected to rise further in the upcoming years.
- Published: September 2023
- Price: $ 4950
- TOC Available:
-
Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Forecast to 2024
The Cancer Registry Software Market is projected to reach USD 91 million by 2024, at a CAGR of 10.4%. Factors such as the increasing prevalence of cancer, favorable government initiatives, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs, and the growing use of cancer patient registry data for post-marketing surveillance are driving the growth of this market. However, factors such as privacy and data security-related concerns are expected to restrain the growth of this market to a certain extent.Elekta (Sweden), Electronic Registry Systems, Inc. (US), Onco, Inc. (US), C/NET Solutions (US), Rocky Mountain Cancer Data Systems (US), and McKesson Corporation (US).
- Published: March 2019
- Price: $ 11000
- TOC Available:
-
Immunotherapy Drugs Market by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029
The global immunotherapy drugs market, valued at US$255.9 billion in 2023, stood at US$285.3 billion in 2024 and is projected to advance at a resilient CAGR of 15.3% from 2024 to 2029, culminating in a forecasted valuation of US$580.6 billion by the end of the period. This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Endoscopic Submucosal Dissection/ESD Market by Product (Gastroscopes & Endoscopes, Injection Agent, Tissue Retractor), Indication (Stomach Cancer, Colon Cancer), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center) - Global Forecast to 2030
The global endoscopic submucosal dissection market, valued at US$0.46 billion in 2024, stood at US$0.50 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of US$0.75 billion by the end of the period. The increasing adoption of endoscopic submucosal dissection (ESD) in Western countries is becoming a significant growth driver for the global ESD market.
- Published: July 2025
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
